Structures postpartum assessment with hemorrhage risk, lactation support, and mood screening. Use when managing postpartum recovery, screening for PPD, or documenting postpartum visits.
Structures postpartum assessment with hemorrhage surveillance, lactation support, mood screening, and recovery milestones per ACOG Committee Opinion No. 736 (the "fourth trimester" framework).
The postpartum period accounts for over 60% of maternal deaths in the United States, with hemorrhage, cardiomyopathy, and hypertensive disorders as leading causes. ACOG's Fourth Trimester initiative (Committee Opinion No. 736) redefined postpartum care from a single 6-week visit to an ongoing process with early contact within 3 weeks and a comprehensive visit by 12 weeks. Postpartum hemorrhage (PPH) remains the most common cause of severe maternal morbidity, and the California Maternal Quality Care Collaborative (CMQCC) OB Hemorrhage Bundle provides the standard of care for staged response.
Equally critical is screening for postpartum depression (PPD), which affects 10–20% of postpartum women. The Edinburgh Postnatal Depression Scale (EPDS) is the validated screening tool, with scores ≥ 10 indicating possible depression and ≥ 13 indicating probable depression requiring intervention.
Apply the CMQCC hemorrhage risk stratification at admission to L&D and re-assess postpartum:
| Risk Level | Criteria | Preparation |
|---|---|---|
| Low | No prior uterine surgery, singleton, ≤ 4 prior births, no bleeding disorder | Type and screen, active management of 3rd stage |
| Medium | Prior cesarean, multiple gestation, grand multiparity, large fibroids, prior PPH, chorioamnionitis, prolonged oxytocin, magnesium | Type and screen, active management, 2 IV access lines, oxytocin running |
| High | Placenta previa/accreta spectrum, platelets < 100K, active bleeding at admission, known coagulopathy, 2+ risk factors for medium | Type and crossmatch 2 units pRBCs, massive transfusion protocol on standby, notify blood bank and anesthesia |
| Stage | Cumulative Blood Loss | Actions |
|---|---|---|
| Stage 0 | Normal | Active management of 3rd stage — oxytocin 10–40 units IV in 1 L LR or 10 units IM |
| Stage 1 | > 500 mL (vaginal) or > 1000 mL (cesarean) | Fundal massage, uterotonics (methylergonovine 0.2 mg IM, carboprost 250 mcg IM, misoprostol 800–1000 mcg PR), IV access ×2, labs (CBC, fibrinogen, coags), notify provider |
| Stage 2 | Continued bleeding or hemodynamic instability | Intrauterine balloon tamponade, tranexamic acid 1 g IV, activate massive transfusion, prepare for OR |
| Stage 3 | Refractory hemorrhage | Surgical intervention: B-Lynch suture, uterine artery ligation, hysterectomy. Interventional radiology (UAE) if available |
Document the following at standardized intervals:
| Timeframe | Assessments |
|---|---|
| Q15 min × 1 hour | Vital signs, fundal tone, lochia volume, bladder distension |
| Q30 min × 1 hour | Vital signs, fundal tone, lochia |
| Q1 hour × 2 hours | Vital signs, fundal tone, pain assessment |
| Then Q4 hours | Routine postpartum assessment |
Key assessment elements:
Administer validated screening tools before discharge and at the postpartum visit:
Document: screening tool used, score, interpretation, referrals initiated, and safety plan if indicated.
Also screen for:
Per ACOG Committee Opinion No. 736, structure the comprehensive postpartum visit: